Janssen's hepatitis C drug simeprevir wins support of FDA panel

10/25/2013 | Medscape (free registration)

An FDA panel endorsed the approval of Janssen R&D Ireland and Medivir's simeprevir, in combination with peginterferon alfa and ribavirin, as a treatment for chronic hepatitis C in patients with compensated liver disease. The drug was particularly recommended for previously untreated patients or those who were unresponsive to previous interferon treatment with or without ribavirin. If approved, the drug would be the third HCV protease inhibitor available in the U.S.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC